A series of evidence addresses the improved efficacy of EGFR inhibitors in limiting glioblastoma tumor growth when used together with radiation [62], or with a histone deacetylase inhibitor [63], or with the mTOR inhibitor rapamycin [64]. This evidence concerns the gene EGFR and glioblastoma.